Skip to content

Study · Animal study (in vivo) · mouse · 2019

5 results

Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models.

Melchers MJ, Teague J, Warn P, Hansen J, Bernardini F, Wach A, Obrecht D, Dale GE, Mouton JW

Antimicrobial agents and chemotherapy26 Feb 2019Cited by 24 (Europe PMC)

PMID30642931 (opens in a new tab)PMCIDPMC6395900 (opens in a new tab)DOI10.1128/aac.01699-18 (opens in a new tab)PepBankPUB-30642931
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In infected neutropenic mice, the unbound AUC/MIC ratio correlated best with murepavadin efficacy.

    In plain wordsIn mice, the unbound AUC/MIC ratio best matched murepavadin efficacy.

    Peptide
    Murepavadin
    Outcome
    Not applicableExposure-response index
    Study

    mousen: not reported in source

    CD-1 neutropenic infected mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · 24 hAs given in this study (mouse).

    Source sentences

    Summary
    Using R2 as an indicator of the best fit, the area under the concentration-time curve for the unbound fraction of the drug (fAUC)/MIC ratio correlated best with efficacy.
    1 context sentence
    Summary · context
    Treatment of CD-1 neutropenic mice was started 2 h after infection using murepavadin at different dosing frequencies for 24 h, and the number of CFU per lung was determined.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In infected neutropenic mice, bacterial stasis required mean murepavadin AUC of 36.83 mg h/liter and unbound AUC of 8.25 mg h/liter.

    In plain wordsIn mice, bacterial stasis required mean murepavadin AUC of 36.83 mg h/liter.

    Peptide
    Murepavadin
    Outcome
    Not applicableAUC for bacterial stasis
    Study

    mousen: not reported in source

    CD-1 neutropenic infected mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · 24 hAs given in this study (mouse).

    Measurements

    AUC
    36.83 mg h/liter
    Static effect
    fAUC
    8.25 mg h/liter
    Static effect

    Source sentences

    Summary
    The mean AUC required to provide a static effect was 36.83 mg h/liter (fAUC = 8.25 mg h/liter), and that to provide a 1-log reduction was 44.0 mg h/liter (fAUC = 9.86 mg h/liter).
    1 context sentence
    Summary · context
    Treatment of CD-1 neutropenic mice was started 2 h after infection using murepavadin at different dosing frequencies for 24 h, and the number of CFU per lung was determined.
  3. 03AnimalAnimal study (in vivo)Pharmacokinetics

    In infected neutropenic mice, a 1-log reduction required mean murepavadin AUC of 44.0 mg h/liter and unbound AUC of 9.86 mg h/liter.

    In plain wordsIn mice, a 1-log bacterial reduction required mean murepavadin AUC of 44.0 mg h/liter.

    Peptide
    Murepavadin
    Outcome
    Not applicableAUC for bacterial reduction
    Study

    mousen: not reported in source

    CD-1 neutropenic infected mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · 24 hAs given in this study (mouse).

    Measurements

    AUC
    44 mg h/liter
    1-log reduction
    fAUC
    9.86 mg h/liter
    1-log reduction

    Source sentences

    Summary
    The mean AUC required to provide a static effect was 36.83 mg h/liter (fAUC = 8.25 mg h/liter), and that to provide a 1-log reduction was 44.0 mg h/liter (fAUC = 9.86 mg h/liter).
    1 context sentence
    Summary · context
    Treatment of CD-1 neutropenic mice was started 2 h after infection using murepavadin at different dosing frequencies for 24 h, and the number of CFU per lung was determined.
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In infected neutropenic mice, the mean murepavadin unbound AUC/MIC for bacterial stasis was 27.78.

    In plain wordsIn mice, the mean murepavadin unbound AUC/MIC for bacterial stasis was 27.78.

    Peptide
    Murepavadin
    Outcome
    Not applicableUnbound AUC/MIC for stasis
    Study

    mousen: not reported in source

    CD-1 neutropenic infected mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · 24 hAs given in this study (mouse).

    Measurements

    fAUC/MIC
    27.78
    Static effect

    Source sentences

    Summary
    The mean static fAUC/MIC was determined to be 27.78, and that for a 1-log reduction was 39.85.
    1 context sentence
    Summary · context
    Treatment of CD-1 neutropenic mice was started 2 h after infection using murepavadin at different dosing frequencies for 24 h, and the number of CFU per lung was determined.
  5. 05AnimalAnimal study (in vivo)Pharmacokinetics

    In infected neutropenic mice, the mean murepavadin unbound AUC/MIC for a 1-log reduction was 39.85.

    In plain wordsIn mice, the mean murepavadin unbound AUC/MIC for a 1-log bacterial reduction was 39.85.

    Peptide
    Murepavadin
    Outcome
    Not applicableUnbound AUC/MIC for bacterial reduction
    Study

    mousen: not reported in source

    CD-1 neutropenic infected mice
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · 24 hAs given in this study (mouse).

    Measurements

    fAUC/MIC
    39.85
    1-log reduction

    Source sentences

    Summary
    The mean static fAUC/MIC was determined to be 27.78, and that for a 1-log reduction was 39.85.
    1 context sentence
    Summary · context
    Treatment of CD-1 neutropenic mice was started 2 h after infection using murepavadin at different dosing frequencies for 24 h, and the number of CFU per lung was determined.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.